2021
DOI: 10.1038/s41586-021-04231-6
|View full text |Cite
|
Sign up to set email alerts
|

Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

Abstract: The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in humans1. CV2CoV is a second-generation mRNA vaccine containing non-modified nucleosides but with optimized non-coding regions and enhanced antigen expression. Here we report the results of a head-to-head comparison of the immunogenicity and protective efficacy of CVnCoV and CV2CoV in non-human primates. We immunized 18 cynomolgus macaques with two doses of … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
118
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
2
1

Relationship

1
9

Authors

Journals

citations
Cited by 101 publications
(124 citation statements)
references
References 40 publications
5
118
0
1
Order By: Relevance
“…The superiority of the modified nucleotide mRNA vaccines is typically attributed to weaker stimulation of innate immune pathways, such as 2′-5′-oligoadenylate synthetase and TLR3, TLR7 and TLR8 activation capable of impeding mRNA expression [ 72 , [76] , [77] , [78] ]. However, as indicated by comparing natural mRNAs from two different suppliers (Trilink vs AmpTec), the efficacy of mRNA vaccines encoding the same antigen depends also largely on mRNA design, sequence optimization and purity as already demonstrated by others [ 12 , 79 , 80 ].…”
Section: Discussionmentioning
confidence: 99%
“…The superiority of the modified nucleotide mRNA vaccines is typically attributed to weaker stimulation of innate immune pathways, such as 2′-5′-oligoadenylate synthetase and TLR3, TLR7 and TLR8 activation capable of impeding mRNA expression [ 72 , [76] , [77] , [78] ]. However, as indicated by comparing natural mRNAs from two different suppliers (Trilink vs AmpTec), the efficacy of mRNA vaccines encoding the same antigen depends also largely on mRNA design, sequence optimization and purity as already demonstrated by others [ 12 , 79 , 80 ].…”
Section: Discussionmentioning
confidence: 99%
“…20g ). These findings indicate that monkeys share overall highly similar transcriptional programs in the immune system with human, and thus may provide an ideal benchmark for investigating the immune response to diseases such as cancer 79 and the current coronavirus disease 2019 (COVID-19) 80 86 .
Fig.
…”
Section: Resultsmentioning
confidence: 88%
“…Although the development of CVnCoV has stopped, these cross-neutralizing immune responses against SARS-CoV-2 variants are promising for the next generation SARS-CoV-2 vaccines which are based on the same mRNA platform and are being optimized for variants [18]. perpetuity.…”
Section: Discussionmentioning
confidence: 99%